PEGS China

China PEGS has crossed the four year, and now has become one of the activities of the biological pharmaceutical industry researcher to participate. The PEGS of China in March 28, 2017 to 30 again held in Shanghai, invited domestic and international influential speakers to show unpublished data and case study, to show the latest international development projects, industry trends and Chinese biotechnology industry's future development potential.

Protein & Antibody Engineering 

As China rises to join the ranks of the global biopharmaceutical powerhouses, the true test lies not only in their regulatory guidance and pathways, but also in their successful discovery and development of novel biotherapeutics. From display libraries to novel antibody generation and engineering of challenging targets, companies need to develop cutting-edge science and creative approaches to beat the competition and be first-to-market.

The Protein & Antibody Engineering track at PEGS China invites academic researchers and industry practitioners to share their passion in the design, discovery and engineering of protein and antibody molecules, and discuss the innovative strategies used to overcome the challenges along the way.

Preliminary Agenda

JOINT KEYNOTE PRESENTATION

Engineering Single-Domain Antibodies for Cancer Therapy

Mitchell Ho, Ph.D., Chief, Antibody Therapy & Senior Investigator, National Institutes of Health

DISPLAY LIBRARIES

A Novel Platform for Human Antibody Discovery Using Yeast Display Antibody Library

Aichi Zhao, Ph.D., President, R&D, OriMabs, Ltd.

Recombinant Antibody Display Libraries – Design, Construction and Selection

Eunice Zhou, Ph.D., Associate Adjunct Professor, Anesthesia, UC San Francisco

PROTEIN & ANTIBODY GENERATION

Generation of Humanized Antibody Transgenic Animal (Camouse) for Producing Human Antibody

Liangpeng Ge, Ph.D., Director, Institute of Bingengineering, Chongqing Academy of Animal Sciences

New Techniques for in vitro Evolution and Selection of Enzymes

Manfred Konrad, Ph.D., Max-Planck Institute for Biophysical Chemistry, Head, Enzyme Biochemistry Laboratory

ENGINEERING OF PROTEINS AND TARGETS

Case Study
Engineering G-Protein Coupled Receptors for High Production and Efficient Folding In Synthetic Environments

Frank Bernhard, Ph.D., Lab Manager, Biophysical Chemistry, Goethe University Frankfurt

Computationally-Driven Engineering of an Anti-Tumor Antibody

Chris Bailey-Kellogg, Ph.D., Professor, Computer Science, University of Dartmouth

DEVELOPMENT OF NOVEL BIOTHERAPEUTICS

Engineering Anti-VEGFR2 X Anti-PDGFR-Beta Bispecific Antibodies for the Treatment of Cancer and Ophthalmological Diseases

Zhenping Zhu, Ph.D., Executive Vice President, Global Biologics R&D, Kadmon Corp, LLC.

Nexmab Antibody-Drug Conjugate for the Treatment of Ovarian Cancer

Sunbae Lee, Ph.D., Senior Research Scientist, R&D Center, Alteogen, Inc.

Protein Aggregation & Stability 

Aggregates and particles are redefining the way companies and regulators approach a molecule – from determining its developability to deciding its formulation. This is because aggregation impacts stability which may affect safety and efficacy and cause immunogenicity.

Thus the study of protein aggregation, particles and sub-visible particles, have become of increasing importance in recent years. The mechanisms of aggregation formation, and its impact on developability and formulation, have become the subject of much study and discussion. Scientists will share aggregation kinetics aimed at understanding the causes of aggregation, while highlighting analytical and formulation strategies targeted at optimizing stability and controlling aggregation.

Preliminary Agenda

JOINT KEYNOTE PRESENTATION

Engineering Single-Domain Antibodies for Cancer Therapy

Mitchell Ho, Ph.D., Chief, Antibody Therapy & Senior Investigator, National Institutes of Health

AGGREGATION FORMATION

Determinant Factor for Aggregation and Fragment Formation: Oxidation

Joy Zhou, Ph.D., Principal Scientist, Associate Director, DP MST, Shire

Protein Aggregation during Formulation and Drug Product Manufacturing and Mitigation Strategies

Mark Yang Ph.D., Director, Fill Finish Development, BioPharmaceutical Development, Genzyme

AGGREGATION ANALYSIS FOR DEVELOPABILITY AND FORMULATION

Aggregation Analysis at High and Low Concentrations

Jennifer McManus, Ph.D., Lecturer, Department of Chemistry, National University of Ireland Maynooth

How to Optimize Stability of Drug Substance and Drug Product through Integration of Rapid and Sensitive Analytical Tools with Rational Approach to Developability Assessment and Early Formulation Development

Danny Chou, Ph.D., President, Compassion BioSolutions, LLC.

Heavy Chain of Mouse IgM Can Be Cleaved Between CH1 and CH2 Domains by a Protease Present in Serum

Tomasz Klaus, MSc, Research Assistant, Malopolska Centre of Biotechnology, Jagiellonian University, Krakow

STABILITY AND DELIVERY DEVICE CHALLENGES

Impact of Product Heterogeneity on Product Biological Activity and Stability in the Context of Bio-therapeutics

Ravish Patel, Ph.D., Scientist, Bioanalytical (Biologics), Analytical Development Lab, EPR Centre for Cancer Research and Bioinformatics Pvt. Ltd. (A Vitane Group of Companies)

Modified Phosphate Buffered Saline (PBS) as a Viable Vehicle for Biotherapeutic Drugs

Tatyana Mezhebovsky, Ph.D., Principal Scientist, BioFormulations, Sanofi US

Immuno-Oncology 

Immuno-oncology is no doubt the hottest fields in biopharma today. By unleashing the patient’s own immune system to destroy cancerous cells, immuno-oncology represents the ultimate in personalized medicine. The success of immune checkpoint blockade with CTLA-4 and PD-1, and encouraging results with agonists, cytokines and vaccines have paved the way for further research and heightened interest in the field.

At CHI’s Inaugural Immuno-Oncology track at PEGS China, we are looking to engage thought leaders and fore-runners in the field to review the current progress in China’s immuno-oncology field, and highlight innovative approaches and cutting-edge technologies in advancing these molecules into the clinic.

Preliminary Agenda

JOINT KEYNOTE SESSION

Multimodal Cancer Therapy - Dynamic Process-Based Immuno-oncology

Bertil Lindmark, M.D., Ph.D., CMO, ASLAN Pharmaceuticals

Rational Combination of Immune-Oncology Agents

Lei Zheng, Ph.D., Assistant Professor, Oncology and Gastrointestinal Cancer, Johns Hopkins University

JOINT SESSION – ANALYTICAL STRATEGIES FOR ENGINEERING T-CELLS

Versatile Strategy for Controlling the Specificity and Activity of Engineered T Cells

Chan Hyuk Kim, Ph.D., Assistant Professor, Biological Sciences, KAIST

Applying a High Content Imaging Assay Platform to Elucidate the Mechanism of Actions of Cancer Immunotherapy

Ming Lei, Senior Research Investigator II, Lead Discovery and Optimization, Bristol-Myers Squibb Company

PIPELINE AND PROGRESS UPDATES IN CHINA’S IMMUNO-ONCOLOGY FIELD

Beyond PD-1: Challenge and Opportunity in Immuno-Oncology

Hongtao Lu, Ph.D., Executive Vice President & CSO, Discovery, Zai Laboratory

Improving the Efficacy of Immuno-Checkpoint Inhibitor through Target Mediated Antibody Recycling and Combination Interventions

Xueming Qian, Ph.D., Chairman & CEO, MabSpace Biosciences

Screening PD1 inhibitors and Beyond

Bo Chen, Ph.D., CEO, Shanghai Junshi

Updates on Alphamab’s Molecules in the Clinic Targeting PDl-1 and CTLA-4

Ting Xu, Ph.D., CEO & President, Alphamab

The Design and Development of Novel Biologics for Cancer Immunotherapies

Jinming Gu, Ph.D., Executive Director, Biologics Discovery, Shanghai Hengrui Pharmaceutical Co., Ltd.

Novel Bispecific Antibody Technology for Cancer Immunotherapeutics

Chengbin Wu, Ph.D., CEO, Epimab

Amgen’s BiTE Bispecific T-Cell Engaging Antibody for Immunotherapy

MingQiang Zhang, Ph.D., Head, R&D, Amgen Asia

Agonist Antibody in Immune-Oncology, in Mono- and Combination Therapies (tentative)

Peter Luo, Ph.D., CEO & Co-Founder, Adagene

 Analytical Characterization of Biotherapeutics 

As China takes on novel and more complex biotherapeutics, one of the biggest challenges is the ability to quickly and accurately characterize these new molecules. Assessment of the critical quality attributes, developability, glycosylation, higher order structure, comparability and biosimilarity, are a critical component toward better product understanding.

The Analytical Characterization of Biotherapeutics track at PEGS China arms scientists with the tools that can speed up innovation, and invites scientists with creative strategies and novel techniques to share their ideas, experiences and solutions to support the development of these exciting new biotherapeutics.

Preliminary Agenda

JOINT KEYNOTE SESSION

Multimodal Cancer Therapy - Dynamic Process-Based Immuno-oncology

Bertil Lindmark, M.D., Ph.D., CMO, ASLAN Pharmaceuticals

Rational Combination of Immune-Oncology Agents

Lei Zheng, Ph.D., Assistant Professor, Oncology and Gastrointestinal Cancer, Johns Hopkins University

JOINT SESSION – ANALYTICAL STRATEGIES FOR ENGINEERING T-CELLS

Versatile Strategy for Controlling the Specificity and Activity of Engineered T Cells

Chan Hyuk Kim, Ph.D., Assistant Professor, Biological Sciences, KAIST

Applying a High Content Imaging Assay Platform to Elucidate the Mechanism of Actions of Cancer Immunotherapy

Ming Lei, Senior Research Investigator II, Lead Discovery and Optimization, Bristol-Myers Squibb Company

OPTIMIZATION AND DEVELOPABILITY

Integrated Technology Solutions to Support Biologics Hit to Lead and Beyond

Han Li, Ph.D., Principal Scientist, Leads Discovery & Optimization, Bristol-Myers Squibb Company

Mutational Approaches to Improve the Biophysical Properties of Single Domain Antibodies

Jamshid Tanha, Ph.D., Senior Research Officer, Human Health Therapeutics Portfolio, National Research Council Canada

STRUCTURE AND FUNCTIONAL CHARACTERIZATION OF NOVEL AND BIOSIMILAR PRODUCTS

Effects of Glycosylation on Biological Activities of Therapeutic Antibodies

Shan Chung, Ph.D., Senior Scientist and Group Leader, Bioanalytical Sciences, Genentech

Oxidative Post-Translational Modification - Impact on Stability and Formulation of Protein Therapeutics

Christian Schoeneich, Ph.D., Professor and Chair, Pharmaceutical Chemistry, University of Kansas Lawrence

Higher Order Structure Analysis of Antibodies by Hydrogen/Deuterium Exchange Mass Spectrometry

Susumu Uchiyama, Ph.D., Associate Professor, Graduate School of Engineering, Osaka University

Physicochemical and Functional Characterization of Biosimilar Bevacizumab

Ravish Patel, Ph.D., Scientist, Bioanalytical (Biologics), Analytical Development Lab, EPR Centre for Cancer Research and Bioinformatics Pvt. Ltd., India